Breast Cancer Therapeutics Market Size expected to witness growth to surpass USD 16 billion by 2023.

1. Breast Cancer Therapeutics Market Size Expected to Witness Growth to Surpass USD 16 billion by 2023.

2. Global Market Scenario Breast Cancer Therapeutics • China breast cancer therapeutics market share accounted for over 15% of the Asia Pacific revenue. • Australia accounted for over 10% and India contributed 3% to overall revenue generation, with the latter expected to grow at 9% CAGR over the forecast timeframe.  • According to WHO statistics, it is the second most prevalent type of the disease globally, and the most widespread type in females. • In women, it accounts for 20% of all invasive and 13% of all female cancers, and is responsible for 15% of all deaths caused by the disease globally, including both females and males. • Every year, around 200,000 new cases in women and nearly 2,000 new cases in men are diagnosed. • This disease occurs when cells in the breast show uncontrolled growth. Malignant tumors may metastatize or growing into the surrounding tissues. • https://www.gminsights.com/industry-analysis/breast-cancer-therapeutics-market

3. Continue..... • It generally either begins in the lobules, which are the milk producing glands, or the inner lining of ducts, the passage that supply milk from lobules. • Tumor occurring in the lobules is lobular carcinoma which represents 80% to 90% of all cases, while one which develops from the ducts is ductal carcinoma, representing 10% to 20% of all cases. • In developed countries, the rates are much higher compared to their developing counterparts. However, in many developing nations, it is now rising abruptly due to changes in lifestyle, reproductive factors, and increased life expectancy. • Mortality from breast cancer is a leading cause of death among women in developing countries, as well as in the developed world. • Approximately 85% to 90% of all cases are caused by genetic abnormality, while the remaining are due to inherited abnormalities.  • High degree of competition, potential side effects, growing number of medication options, and substitute branded drugs availability may adversely impact revenue in the coming years. • Get more detail @ https://www.gminsights.com/industry-analysis/breast-cancer-therapeutics-market

4. Continue..... • On the basis of drug class, the industry is categorized into five major segments, namely, anti-metabolites, HER2 inhibitors, aromatase inhibitors, mitotic inhibitors, and hormone receptors. • Based on the clinical study, the breast cancer therapeutics market can be segmented into Phase I, Phase II, and Phase III drugs. Of these, Phase III drugs are BKM120, Palbociclib (PD-0332991) + Exemestane, Neratinib, DOXIL, ABP 980, NKTR-102, NK105, CT-P6, and Olaparib. • Neratinib (developed by Puma Biotechnology), a clinical trial phase IIIdrug, will generate maximum revenue by 2023. It is highly powerful as an irreversible tyrosine kinase inhibitor (TKI). • Available products comprise a wide range of treatment options, including hormonal, combination, targeted and chemotherapies. Chemotherapy remains the most important class of drugs for treatment; however, the trend of using targeted drugs is on the rise. • Treatment for the disease has been modernized in the past decades with increasing usage of targeted therapies. Perpendicular rise in the occurrence of disease makes it an industry where novel molecules and therapies are imperative. • Get more detail @ https://www.gminsights.com/industry-analysis/breast-cancer-therapeutics-market

5. Latest Research Report On Breast Cancer Therapeutics Market@ https://www.gminsights.com/industry-analysis/breast-cancer-therapeutics-market Download Latest Report Table of Contents @ https://www.gminsights.com/request-toc/upcoming/466

6. Stay In Touch You can visit us at: www.gminsights.com